Pulmonary Hypertension
At Johnson & Johnson, we continue to build on our decades-long effort to transform pulmonary arterial hypertension (PAH) from a deadly disease into a manageable condition to help patients live better everyday lives.
Expand
Collapse
Our vision is to transform pulmonary hypertension (PH) into a long-term, manageable condition, so that patients can live a normal life.
Focus areas
Related stories
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
We are committed to partnering with those whose innovative thinking will bring new and creative solutions to the field of medicine
Related links